U.S. Markets closed

Array BioPharma Inc. (ARRY)


NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
8.24-0.14 (-1.67%)
At close: 4:00PM EDT
People also watch
EXELARQLCLDXRIGLFOLD
Full screen
Previous Close8.38
Open8.48
Bid7.95 x 300
Ask8.35 x 200
Day's Range8.15 - 8.49
52 Week Range3.10 - 13.40
Volume2,105,088
Avg. Volume3,437,179
Market Cap1.41B
Beta1.74
PE Ratio (TTM)-11.44
EPS (TTM)-0.72
Earnings DateAug 2, 2017 - Aug 7, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.33
Trade prices are not sourced from all markets
  • Zacks2 days ago

    New Strong Sell Stocks for July 20th

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

  • American City Business Journals4 days ago

    Colorado biotech makes deal with industry giant

    A Boulder biotech said it's made a deal with an industry giant to develop drugs for autoimmune disorders. Array BioPharma Inc. (ARRY) said it's made a deal with giant Amgen Inc. (AMGN) of Thousand Oaks, California to take advantage of Array's inflammatory disease discoveries. "The identification of this novel target, along with our team's deep experience in kinase inhibitor chemistry, gives us confidence that our efforts will result in a drug which will address a significant unmet medical need for patients with inflammatory disease," said Nicholas Saccomano, chief scientific officer at Array, in a statement.

  • PR Newswire4 days ago

    Amgen And Array BioPharma Announce Preclinical License And Collaboration Agreement In Inflammation

    THOUSAND OAKS, Calif. and BOULDER, Colo., July 18, 2017 /PRNewswire/ -- Amgen (AMGN) and Array BioPharma (ARRY) today announced a collaboration agreement for the discovery and development of novel drugs for autoimmune disorders. "We are pleased to enter this collaboration with Array that builds on our continued focus in inflammation, one of Amgen's key strategic areas of interest," said Flavius Martin, M.D., vice president of Research, Inflammation and Oncology at Amgen.